We work on some of the most complex molecules in development. Our scientists write about it, present on it, and share what they have learned, so you can move your program forward with more confidence. Drug product, nanomedicine, bioanalysis, drug substance. Written by the people who deliver these programs every day.
Live conferences and on-demand webinars where you can connect with our scientific team.
Join CHDR and Ardena on Oct 19, 2026 to see how biomarker validation and translational medicine demonstrate CNS target engagement in neurodegenerative disease.
Talk formulation, drug product and bioanalysis with our specialists at booth 2012.
Moving molecules from discovery into development, in San Diego.
Insights and perspectives from our team on industry trends and scientific advances.
Biomarkers create the biological context for your study, turning a clinical question into a measurable answer. This article outlines how to use Ardena’s new Biomarker Catalogue to streamline the path from marker selection to quotation. Few decisions in a development programme carry as much weight per sample as the choice of biomarkers. The right combination […]
Tablets remain the way most of the world takes its medicine – yet developing a robust one is still surprisingly empirical. With the new STYL’ONE Evo Compaction Simulator at our Ghent site, we can now predict how a formulation will behave on a production tablet press or roller compactor from the very first development batch, […]
For most of the last decade, protein quantification in biological matrices has been the territory of the ligand binding assay. That has not changed, but the boundaries have. A new perspective from the European Bioanalysis Forum (EBF) Hybrid MS team, published in Bioanalysis, gathers seven case studies from pharmaceutical companies and CROs showing where liquid […]
Real-world examples of how our expertise has helped partners advance their programs.
Proof of Structure (PoS) is the comprehensive analytical confirmation that a synthesized compound corresponds exactly to its intended chemical identity, including its molecular formula, connectivity, stereochemistry and purity profile. In the pharmaceutical industry, accurate characterization of a molecular structure, including its solid-state identity, is a fundamental requirement that underpins every stage of drug development, from […]
Poor aqueous solubility remains a formidable barrier in drug development, with approximately 90% of new chemical entities facing significant challenges in achieving effective bioavailability. To overcome these limitations, pharmaceutical developers frequently employ solubility enhancement techniques, ranging from particle size reduction to solid-state modifications and advanced formulation-based strategies. At Ardena, our approach emphasizes salt screening, lipid-based […]
A shift to a four-arm, multi-dose Phase IIa protocol introduced new requirements for dosing accuracy, traceability, and patient usability. Learn how Ardena designed a modular secondary packaging solution that integrated existing blister configurations and enabled seamless execution of the updated clinical design.
In-depth scientific papers from our experts on emerging methods and technologies.
Delumping is an established operation in pharmaceutical manufacturing, used to produce more homogeneous, free-flowing powders across drug substance and drug product processes. When agglomeration is left unaddressed, it can affect powder flow, charging, homogeneity, downstream processing, cycle time and yield. In this technical paper, Kim Geurts, Scientist PR&D and Manufacturing, Enabling Chemistry, explains how Ardena […]
Nanomedicines demand tight control over particle properties, reproducibility, and scalability, yet conventional batch methods often struggle to deliver all three. In this whitepaper, Ardena’s nanomedicines experts Mark van Eldijk and Andy Bänziger explore how flow manufacturing can enable more consistent nanoparticle production, simplify scale-up, and support robust development pathways from early-stage research through GMP manufacturing. […]
The ICH has released a draft consolidated guideline (ICH Q1) that unifies the previous Q1A–Q1F series into a single global standard. This revision simplifies stability requirements, integrates lifecycle management, and expands the scope to advanced therapies and drug-device combinations. This whitepaper provides a clear overview of the key changes — from predictive tools and modeling […]
Conversations with our scientists and partners on drug development science.
What does it take to move innovative science from the lab toward the patient? In this episode of We Know Development™, Mark van Eldijk, Vice President of Science and Technology at Ardena, discusses nanoparticles, advanced drug development, and the challenges of translating complex technologies into medicines that can make a real impact. Discover the science, […]
Welcome to We Know Development™, a podcast from Ardena about the people, decisions, and expertise behind drug development. Drug development is often described through science, technology, quality, and regulation. All of those are essential. But behind every successful program are people making decisions, navigating uncertainty, solving complex challenges, and building trust. In We Know Development, […]
